52gMn production route for multi-modal imaging applications

The radionuclide 52gMn is of significant medical interest for the innovative PET-MRI multimodal imaging technique. In this study we compare its standard cyclotron production route natCr(p, x)52gMn with the alternative reaction natV(α, x)52gMn. The theoretical calculations are performed by a suitable tuning of the nuclear level density parameters of the TALYS reaction code, with the aim to obtain a good agreement with the experimental cross sections. The production route with natV results in a more favorable radionuclidic purity than with natCr. Dosimetric studies are performed to establish the time frame in which 52gMn can be used with an acceptable dose to the patient

Therapeutic application of a mixture of 64/67Cu radioisotopes

Copper radioisotopes, such as 64Cu and 67Cu, could be useful tools for diagnosis and therapy of cancers, due to the increased accumulation of Cu2+ ions in the tumor site. While 64Cu can be produced with high specific activity using low-energy biomedical cyclotrons and it is already commercially available, 67Cu production is more challenging, due to the difficulties to obtain a high yield without the co-production of other Cu-isotopes, especially 64Cu. Due to the favorable decay characteristics of both 64/67Cu radioisotopes, in this work the possibility of using a mixture of them for therapeutic purposes has been evaluated

Effective dose increase of cyclotron-produced 99mTc labelled radiopharmaceuticals

Alternative Technetium-99m production via 100Mo(p,2n)99mTc reaction route using medical cyclotrons, is reliable and relatively cost-effective1. However, it was found that the 99mTc thus produced contains small quantities of several 9xTc radioisotopes (93mTc, 93Tc, 94Tc, 94mTc, 95Tc, 95mTc 96Tc and 97mTc)2. The aim of this work was to estimate the effective dose-increase (DI) due to the contribution of 9xTc contaminants, after intravenous injection of four radiopharmaceuticals prepared with cyclotron-produced 99mTc (CP-99mTc) using 99.05% 100Mo-enriched molybdenum metallic targets